SOL S.p.A. (QOL)

Overview

Sutro Biopharma, Inc. stands as a pivotal clinical-stage oncology company, distinguished by its innovative approach towards treating cancer. Established in 2003 and originally named Fundamental Applied Biology, Inc., the company has since evolved, situating its headquarters in South San Francisco, California. Sutro Biopharma is at the forefront of developing site-specific and novel-format antibody drug conjugates (ADC) through its proprietary cell-free protein synthesis platforms, XpressCF, and XpressCF+. These advancements are tailored to address the unmet needs within oncology, focusing on delivering cutting-edge treatments for patients battling cancer. Additionally, Sutro Biopharma actively engages in collaboration and license agreements with esteemed entities like Merck, Celgene Corporation, EMD Serono, and Astellas Pharma Inc., aiming to expand the horizons of its ADC technologies across various cancer targets and autoimmune disorders.

Products and Services

• STRO-001: An innovative antibody drug conjugate (ADC) specifically targeting CD74, a cancer-associated antigen. Currently in Phase 1 clinical trials, STRO-001 is designed for patients suffering from multiple myeloma and non-Hodgkin lymphoma. This treatment exemplifies Sutro Biopharma's commitment to addressing cancers with a high unmet medical need through targeted therapy.

• STRO-002: This ADC is directed against folate receptor-alpha, a therapeutic target associated with ovarian and endometrial cancers. STRO-002 is in Phase 1 clinical trials, representing a strategic focus on gynecological malignancies by engaging in cutting-edge research to provide novel treatment options for patients.

• STRO-003: A pre-clinical product candidate, STRO-003 is an ADC targeting the anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), with potential applications in the treatment of solid tumors. This initiative underscores Sutro Biopharma’s dedication to expanding its ADC portfolio into broader oncology indications.